Berry Genomics, Illumina Seeking CFDA Approval for NIPT on Customized NextSeq 500 | GenomeWeb

NEW YORK (GenomeWeb) – Chinese genetic testing firm Berry Genomics and Illumina have co-developed a next-generation sequencing system and are currently seeking approval for clinical applications from the Chinese Food and Drug Administration, the companies said today.

Under their partnership, the firms have developed a customized sequencer that is based on Illumina's NextSeq 500 and have integrated it with Berry's Bambni noninvasive prenatal test, which includes a PCR-free library prep kit and proprietary RUPATM analysis software.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.